Insight Molecular Diagnostics outlines $2B annual market opportunity and signals rapid commercialization push for GraftAssureDx

What: Insight Molecular Diagnostics outlined a $2B annual market opportunity for GraftAssureDx.
Why: The company is signaling a rapid commercialization push for the product.
Signal: A significant market opportunity has been identified, prompting accelerated growth plans.
Target: The company is targeting a $2B annual market share with GraftAssureDx.
Risk: The rapid commercialization push may increase operational and financial risks for Insight Molecular Diagnostics.